Wellington Management Group
TRDA icon

Wellington Management Group’s Entrada Therapeutics TRDA Stock Holding History

Wellington Management Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Sell
1,034,782
-9,976
-1% -$114K ﹤0.01% 1169
2025
Q4 		$10.7M Buy
1,044,758
+90,339
+9% +$761K ﹤0.01% 1236
2025
Q3 		$5.54M Sell
954,419
-106,297
-10% -$622K ﹤0.01% 1417
2025
Q2 		$7.13M Buy
1,060,716
+7,402
+0.7% +$59.6K ﹤0.01% 1300
2025
Q1 		$9.52M Buy
1,053,314
+21,488
+2% +$268K ﹤0.01% 1211
2024
Q4 		$17.8M Buy
1,031,826
+2,457
+0.2% +$44.5K ﹤0.01% 1008
2024
Q3 		$16.4M Sell
1,029,369
-4,558
-0.4% -$71.8K ﹤0.01% 1015
2024
Q2 		$14.7M Buy
1,033,927
+7,087
+0.7% +$101K ﹤0.01% 1034
2024
Q1 		$14.6M Sell
1,026,840
-20,940
-2% -$296K ﹤0.01% 1021
2023
Q4 		$15.8M Buy
1,047,780
+2,128
+0.2% +$31.5K ﹤0.01% 1000
2023
Q3 		$16.5M Buy
1,045,652
+26,144
+3% +$412K ﹤0.01% 975
2023
Q2 		$15.4M Buy
1,019,508
+5,055
+0.5% +$69.6K ﹤0.01% 1005
2023
Q1 		$14.7M Buy
1,014,453
+4,102
+0.4% +$54.8K ﹤0.01% 1008
2022
Q4 		$13.7M Buy
1,010,351
+3,105
+0.3% +$54.4K ﹤0.01% 1003
2022
Q3 		$15.9M Sell
1,007,246
-528,637
-34% -$6.71M ﹤0.01% 980
2022
Q2 		$18.7M Sell
1,535,883
-1,007,219
-40% -$7.64M ﹤0.01% 959
2022
Q1 		$23.8M Sell
2,543,102
-570,904
-18% -$6.12M ﹤0.01% 977
2021
Q4 		$52.8M Buy
+3,114,006
New +$75.5M 0.01% 799

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group's TRDA Position: Q1 2026 in Review

Wellington Management Group reduced its Entrada Therapeutics (TRDA) stake by 0.95% in Q1 2026, selling an estimated $114K and leaving 1,034,782 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Wellington Management Group first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $52.8M in Q4 2021. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Wellington Management Group held 1,034,782 shares of Entrada Therapeutics worth $13.1M as of Q1 2026.
  • Wellington Management Group sold 9,976 Entrada Therapeutics shares in Q1 2026, an estimated $114K.
  • Entrada Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1169 holding.
  • Wellington Management Group first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Wellington Management Group's Entrada Therapeutics position peaked at $52.8M in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.